Related Experiment Video

Updated: Jul 25, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

671

Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes

Almudena Castro Conde1, Domingo Marzal Martín2, Raquel Campuzano Ruiz3

  • 1Cardiology Department, University Hospital La Paz, 28046 Madrid, Spain.

Journal of Clinical Medicine
|June 28, 2023
PubMed

Insights

Type 2 diabetes management requires early intervention focusing on lifestyle and medications proven to reduce complications. This consensus emphasizes comprehensive vascular risk control, including weight management and new protective drugs.

Area of Science:

  • Endocrinology and Cardiology
  • Public Health

Background:

  • Type 2 diabetes (T2DM) is a major global health issue.
  • It significantly increases the risk of atherosclerotic vascular disease, heart failure, chronic kidney disease, and mortality.
  • Early intervention is crucial for managing T2DM and its severe complications.

Purpose of the Study:

  • To provide an updated, comprehensive approach to managing Type 2 diabetes and its complications.
  • To emphasize global cardiovascular risk control alongside metabolic control.
  • To guide specialists in optimizing patient care.

Main Methods:

  • Development of a consensus document by a multidisciplinary team (endocrinologists, primary care physicians, internists, nephrologists, cardiologists).
  • Focus on evidence-based strategies for T2DM management.
  • Review of current therapeutic options and their cardiovascular benefits.

Main Results:

  • Highlights the importance of intensifying lifestyle changes in early T2DM phases.
  • Recommends prioritizing drugs proven to reduce cardiovascular complications.
  • Advocates for including weight management as a therapeutic goal.
  • Supports the use of GLP-1 receptor agonists and SGLT2 inhibitors for cardiovascular protection.

Conclusions:

  • A holistic approach is necessary for managing T2DM, integrating metabolic and vascular risk control.
  • Deprescribing medications without proven cardiovascular benefit is recommended.
  • GLP-1 receptor agonists and SGLT2 inhibitors are established as key cardiovascular protective agents in T2DM management.
Keywords:
GLP-1 receptor agonistsSGLT2 inhibitorscardiovasculardiabetesglycated hemoglobinrenal

More Related Videos

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression04:36

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression

Published on: January 12, 2024

1.1K
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

226

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
319
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
48
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
40
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
605